A61K 51/1045
Against animal or human tumor cells or tumor cell determinants
Official title: {against animal or human tumor cells or tumor cell determinants}
A61K51/1045 (Against animal or human tumor cells or tumor cell determinants) appears on 805 US grants and 1,148 published applications in this corpus.
Search patents in A61K- Granted patents
- 805
- Published applications
- 1,148
- Assignees
- 439
- Inventors
- 1,677
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 3 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 4 | 0 |
| 1987 | 2 | 0 |
| 1988 | 3 | 0 |
| 1989 | 9 | 0 |
| 1990 | 10 | 0 |
| 1991 | 8 | 0 |
| 1992 | 10 | 0 |
| 1993 | 6 | 0 |
| 1994 | 6 | 0 |
| 1995 | 10 | 0 |
| 1996 | 14 | 0 |
| 1997 | 19 | 0 |
| 1998 | 24 | 0 |
| 1999 | 17 | 0 |
| 2000 | 19 | 0 |
| 2001 | 13 | 4 |
| 2002 | 8 | 23 |
| 2003 | 11 | 31 |
| 2004 | 11 | 37 |
| 2005 | 11 | 37 |
| 2006 | 12 | 36 |
| 2007 | 16 | 30 |
| 2008 | 27 | 35 |
| 2009 | 23 | 52 |
| 2010 | 27 | 56 |
| 2011 | 30 | 41 |
| 2012 | 32 | 49 |
| 2013 | 33 | 45 |
| 2014 | 34 | 52 |
| 2015 | 30 | 49 |
| 2016 | 34 | 63 |
| 2017 | 42 | 52 |
| 2018 | 27 | 44 |
| 2019 | 32 | 47 |
| 2020 | 26 | 52 |
| 2021 | 21 | 38 |
| 2022 | 36 | 68 |
| 2023 | 29 | 49 |
| 2024 | 27 | 77 |
| 2025 | 27 | 40 |
| 2026 | 17 | 41 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 51/1072The tumor cell being from the reproductive system126
- A61K 51/1051The tumor cell being from breast118
- A61K 51/1048The tumor cell determinant being a carcino embryonic antigen101
- A61K 51/1063The tumor cell being from stomach or intestines82
- A61K 51/1057The tumor cell being from liver or pancreas76
- A61K 51/1069The tumor cell being from blood cells71
- A61K 51/106The tumor cell being from kidney or bladder47
- A61K 51/1066The tumor cell being from skin29
All 9 subgroupsShow fewer
Recent patents
- Antibody conjugates and uses thereof6 Oct 2026US 12,753,242 B2GlycoNex Inc.
- Urokinase plasminogen activator receptor-targeted radiopharmaceutical22 Sep 2026US 12,741,039 B2Monopar Therapeutics Inc.
- Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer22 Sep 2026US 12,741,964 B2Cornell University
- Combination therapy for treating cancer25 Aug 2026US 12,714,759 B2City of Hope
- Nanobodies binding TROP2 and uses thereof25 Aug 2026US 12,715,931 B2Biosion Inc.
- Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer1 Oct 2026US 2026/0295100 A1Memorial Sloan Kettering Cancer Center
- Anti-mesothelin antibodies10 Sep 2026US 2026/0265405 A1Nona Biosciences (Suzhou) Co., Ltd.
- Combined Therapy with Nanoparticles and Radiopharmaceuticals3 Sep 2026US 2026/0256963 A1Centre National De La Recherche Scientifique
- Anti-ceacam5/6 dual-binding antibodies3 Sep 2026US 2026/0258125 A1Nona Biosciences (Suzhou) Co., Ltd.
- Humanised Anti Kallikrein-2 Antibody3 Sep 2026US 2026/0258157 A1Janssen Biotech, Inc.
Most cited
By later US patents
- Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers510US 4,331,647 A1982
- Compositions for targeting the vasculature of solid tumors254US 6,051,230 ABoard of Regents, The University of Texas System · 2000
- Methods for treating the vasculature of solid tumors252US 5,855,866 ABoard of Regenis, The University of Texas System · 1999
- Tumor localization and therapy with labeled antibodies to cell surface antigens217US 4,444,744 A1984
- Methods for targeting the vasculature of solid tumors215US 5,776,427 ABoard of Regents, The University of Texas System · 1998